Woman depicting a cancer patient.

For adults with triple-negative breast cancer (negative for estrogen and progesterone hormone receptors and HER2) that has spread to other parts of the body (metastatic) or cannot be removed by surgery, and who have received two or more prior treatments, including at least one treatment for metastatic disease.

TRODELVY was studied in 529 patients randomized for treatment with TRODELVY (n=267) or the physician's choice of single-agent chemotherapy (traditional chemotherapies). These included eribulin, capecitabine, gemcitabine, or vinorelbine. The trial tested median Progression-Free Survival (PFS). PFS is how long a treatment stops the growth or spread of mTNBC in half the people who take it. Some patients taking TRODELVY showed no signs of their mTNBC getting worse for at least 4.8 months vs 1.7 months for patients taking traditional chemotherapies.

Not actual patients.